Drs Austin and Russell comment: Drs Ross and Fleming raise an interesting point in relation to the exercise testing which we used to support our questionnaire survey carried out in March and April 1992. We know of no epidemiological study which has correlated the prevalence of bronchial hyperactivity to exercise with new asthma episodes, but it is reasonable to suppose that seasonal variations in general practitioner returns will be more closely related to variations in the prevalence of various trigger factors, including pollens, than to variations in underlying bronchial hyperactivity. Nevertheless, allergens are known to affect bronchial hyperactivity, and the prevalence of exercise induced bronchoconstriction might thus be influenced by the date of study.
We have therefore reanalysed our data to look for possible seasonal effects. If exercise tests performed in June are omitted, the overall prevalence of exercise induced bronchial hyperactivity rises to 9-6% compared with 8-9% when data for June tests are included.
Although weekly general practitioner returns for new asthma episodes in school aged children show a rise in late June/early July, this is small compared with the sharp rise in September.' In Highland Region, figures from one general practice suggest that there is little difference for out of hours consultations for childhood asthma between April and June, although the numbers are low (four calls in April, one in May, and two in June) (figures courtesy of Ardlarich Medical Practice, Inverness).
We believe it is unlikely that pollen levels had any major influence on our results. In the north of Scotland the pollen count is low because of the climate (pollen tends not to hang in the air of the prevailing winds, and pollen production is lower and occurs later than elsewhere in UK) and the relatively sparse vegetation, especially in Skye. In any case, the tests in Skye were performed on 8th May 1992, too soon to be influenced by the seasonal effects proposed by Ross and Fleming. Gotzsche et al concluded that 'no patient with structural abnormalities of the X chromosome had cardiovascular malformations'. This is true for their 13 non-mosaic patients but in fact 4/46 of their patients with cardiovascular problems did have a cell line containing a ring or iso (X) chromosome. It is likely that these four individuals began life with a non-mosaic karyotype and that a 45 X cell line arose later as the abnormal X chromosomes were lost during cell division. It seems, therefore, that it is the presence of a 45 X cell line at an early stage of development that might influence whether a cardiovascular abnormality is likely to be present or not.
Why should this be so? It has been suggested that a gene which is present on both the X and the Y chromosome and which escapes X inactivation may be responsible for the somatic features of Turner's syndrome.3
An individual must possess two functioning copies of this gene in order not to manifest Turner's syndrome characteristics. Structurally abnormal X chromosomes may still express this gene which is proposed to lie on the long arm of the X at Xql3, close to the centromere and the X inactivation centre. Only a single copy of this gene can be expressed in cells which contain a 45 X cell line. This gene may have a primary role in the causation of cardiovascular malformations or a secondary role because its absence gives rise to lymphoedema.4 In our study lymphoedema was documented in 79% patients with only a 45 X cell line and in 33% patients with structural X chromosome abnormalities.
We are in agreement with Gotzsche and other authors who have suggested an increased prevalence of cardiovascular malformations in Turner's syndrome patients with a 45 X karyotype. However, although the incidence of cardiovascular abnormalities is low in patients with non-mosaic structural abnormalities, patients who are mosaics for ring (X) or iso (X) with a 45 X cell line or who have X chromosomes or markers lacking the Xql3 region may still be a significant risk of heart problems and should be screened for these. We would like to report our observations on the changes in renal phosphate handling and markers of bone turnover in a 7 year old girl with hypophosphataemic rickets treated with growth hormone over an initial seven month period. She was originally referred for an endocrine assessment because of her short stature. Although she was exceedingly short for her age (height SD score -3 9), there was no evidence of deformity of her legs and no active rickets. An insulin tolerance test with adequate hypoglycaemia demonstrated a peak growth hormone response of 7-5 ,ug/l (15 mU/l). In view of this and her short stature it was decided to give her a therapeutic trial of growth hormone in a dose of 0-6 IU/kg/week increased to 0 75 IU/kg/week after three months given as six daily injections/week.
CATHERINE PARCHMENT
Over a seven month period she gained 4-4 cm in height, her height SD score improved from -3 9 to -3-7 and height velocity SD score from -1-8 to -0-1. On the same doses of phosphate and vitamin D her plasma phosphate rose from 0 99 mmol/l to 1-37 mmol/l at three months and then dropped to 1-02
